May 8, 2025 04:05 PM EDTUpdated 07:08 PM

Illumina forecasts $85M in tariff costs, decrease in China sales

Jared Whitlock

Features Editor

Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said Thursday during its quarterly earnings …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Illumina forecasts $85M in tariff costs, decrease in China sales

Jared Whitlock

Features Editor

Sign up to read this article for free.

GSK awaits Nucala decision after FDA target date passes

Takeda announces handful of pipeline cuts in effort to ‘pivot resources’

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

AI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'

AstraZeneca loses appeals court fight over IRA drug price negotiations

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Il­lu­mi­na fore­casts $85M in tar­iff costs, de­crease in Chi­na sales

Jared Whitlock

Features Editor

Sign up to read this article for free.

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Illumina forecasts $85M in tariff costs, decrease in China sales

GSK awaits Nucala decision after FDA target date passes

Takeda announces handful of pipeline cuts in effort to ‘pivot resources’

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

AI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'

AstraZeneca loses appeals court fight over IRA drug price negotiations

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges